Quarterly report pursuant to Section 13 or 15(d)

Dispositions - Additional Information (Details)

v3.8.0.1
Dispositions - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Nov. 04, 2015
Feb. 28, 2017
Sep. 30, 2017
Sep. 30, 2017
Mar. 31, 2017
Asset Purchase Agreement and Ology Bioservices License Agreement [Member]          
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]          
Cash payments from Ology Bioservices   $ 4,500,000      
Number of shares removed from obligation to issue of common stock   23,008      
Contingent upon achieving certain specified future operating objectives   $ 3,000,000      
Amount entitled to receive     $ 4,600,000 $ 4,600,000 $ 1,600,000
Milestone payment earned     3,000,000    
Amount received from sale of discontinued operation     300,000 700,000  
Remaining consideration amount receivable     3,900,000 3,900,000  
Remaining amount receivable in monthly installments     2,700,000 2,700,000  
Remaining amount receivable in quarterly installments     $ 1,200,000 $ 1,200,000  
Biodefense Business [Member]          
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]          
Sales of business, number of common stock shares eligible to receive 23,008        
Royalties receivable percentage on net sales 15.00%        
Biodefense Business [Member] | Maximum [Member]          
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]          
Cash payments from Ology Bioservices $ 4,500,000